CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

SirolimusWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1822 Placebo Wiki 0.04

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.04
D007239 Infection NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.04

There are 2 clinical trials

Clinical Trials

1 Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial)

The main objective of our study is to determine if treatment with sirolimus can improve clinical outcomes in hospitalized patients with COVID-19. The investigators will employ a randomized, double blind, placebo-controlled study design. 30 subjects will be randomized in a 2:1 fashion to receive sirolimus or placebo. Sirolimus will be given as a 6mg oral loading dose on day 1 followed by 2mg daily for a maximum treatment duration of 14 days or until hospital discharge, whichever happens sooner. Chart reviews will be conducted daily to determine changes in clinical status, concomitant medications and laboratory parameters. Study specific biomarkers will be measured at baseline and then at days 3, 7 and 14.

NCT04341675 COVID-19 Drug: Sirolimus Drug: Placebo
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Death or progression to respiratory failure requiring advanced support measures, either due to inadequate ventilation (non-invasive or invasive mechanical ventilation) or inadequate oxygenation (CPAP* or high flow supplemental oxygen at rates ≥ 15 liters/minute), in patients given sirolimus compared to the placebo group. * CPAP use for known obstructive sleep apnea will not be considered as disease progression.

Measure: Proportion of patients who are alive and free from advanced respiratory support measures at day 28.

Time: 28 days

Secondary Outcomes

Description: Progression to a higher level of care, e.g. ICU

Measure: Proportion of patients who require escalation in care

Time: 14 days

Description: Change over time in study-specific biomarkers (LDH, Ferritin, D-dimer, lymphocyte count)

Measure: Change over time in study-specific biomarkers (LDH, Ferritin, D-dimer, lymphocyte count)

Time: 14 days

Description: Survival to hospital discharge

Measure: Proportion of patients surviving to hospital discharge

Time: days

Description: Incidence and type of adverse events

Measure: Drug safety profile

Time: 14 days

Description: Number of days spent on advanced respiratory support measures

Measure: Duration of advanced respiratory support

Time: days

Description: Length of hospitalization (in patients who survive to discharge)

Measure: Duration of hospital stay

Time: days

Description: Number of days between study initiation and death (in the subset of patients who die during the hospitalization)

Measure: Time from treatment initiation to death

Time: days

Description: Time (in days) to resolution of fever

Measure: Time to resolution of fever

Time: 14 days

Description: Patients needing off-label treatments such as Anti-IL-6 inhibitors at the discretion of primary clinicians

Measure: Proportion of patients who require initiation of off-label therapies

Time: 14 days

2 Efficacy and Safety of Sirolimus for Treating COVID-19 Infection

This research is planned to illustrate the efficacy and safety of sirolimus as an adjuvant agent to the standard treatment protocol against COVID-19 infection

NCT04461340 COVID 19 Drug: Sirolimus
MeSH:Infection

Primary Outcomes

Description: The duration from start of treatment to normalization of pyrexia, respiratory rate ,O2 saturation and relief of cough that is maintained for at least 72 hours.

Measure: Time to clinical recovery

Time: 14-28 days

Description: Two successive negative COVID-19 PCR analysis tests 48-72 hours apart

Measure: Viral clearance

Time: 14 days

Secondary Outcomes

Description: Evaluate the lung extension of pneumonia at day 14

Measure: radiological lung extension

Time: 14 days

Description: incidence and type of adverse events

Measure: drug adverse events

Time: 28 days

Description: number of deaths to total number of patients

Measure: 28 day mortality

Time: 28 day

Description: deteriorated patients who need admission to intensive care unit

Measure: intensive care unit (ICU) admission rate

Time: 28 days

Description: duration from hospitalization to discharge

Measure: Duration of hospital stay

Time: 28 days

Related HPO nodes (Using clinical trials)

HP:0002090: Pneumonia
Genes 220
KMT2D OSTM1 GBA RSPH1 DOCK8 NKX2-1 RNU4ATAC SPAG1 RAG1 MCIDAS AFF4 TNFRSF13C DNAH1 NOTCH3 CD19 ALMS1 NADK2 UNC119 SFTPC FOXN1 CD79B CFAP221 CD81 SAMD9 MED25 ZAP70 RAG2 IGLL1 DNAAF1 RPGR STK36 LTBP3 PLOD1 DNAH9 BTK TERT COL11A2 OFD1 TNFRSF11A LRBA RSPH4A CD19 NME8 SMARCD2 GAS8 CFTR TNFRSF13B CCDC65 CFAP298 COL11A2 RAG1 ORC6 P4HTM MAN2B1 CFAP300 JAK3 CACNA1C ICOS SETBP1 TNFRSF13C SPEF2 LIG4 NIPBL STAT3 ZMYND10 IL7R MAN2B1 HLA-DQA1 IL21R SELENON SP110 ACADVL CCDC39 ARMC4 NSMCE3 NFIX DNAI2 ACP5 PTPRC ZAP70 KIAA0586 FCGR2A NFKB2 NEK10 MTHFD1 EGFR RYR1 ADA DNAI1 TGFB1 DNAAF6 IL2RG KCNJ6 DCLRE1C CCDC103 IGHM GNPTAB DNAAF4 PNP CFB DCLRE1C TAF1 CARD11 USB1 ADA ICOS FMO3 IL2RG HLA-DQB1 GFI1 SFTPA2 ICOS CD3D FOXJ1 CRLF1 ELANE IL2RG SRP54 NFKB1 PANK2 GAS2L2 CD247 IRF8 GAS8 RAG2 CCDC151 WAS ZBTB24 CD3E DNAL1 EXTL3 SLC35A1 NCF1 TK2 MS4A1 IFNGR1 RNF168 RMRP RSPH9 NHLRC1 MUC5B TNFRSF13C DNAH5 DNMT3B RNF125 EPM2A TTC12 JAK3 LEP RAC1 CYBA PGM3 NOS1 DDR2 AFF4 TBC1D24 CHD7 TNFRSF13B OFD1 DNAI1 RANBP2 TCIRG1 DNAJB13 CR2 CCDC40 IL2RG NCF2 RAG2 SLC25A24 SGCG WDR19 FOXP3 RNU4ATAC ACTA1 UBB CFAP410 BTK TTC25 CARD11 DNAAF2 CXCR4 MASP2 DRC1 TBCD DCLRE1C CYBB RSPH3 LRRC6 PIGN TNFSF12 DNAAF5 CCNO CSPP1 CR2 SLC35C1 HYDIN TIMM8A NBN NFKB2 CCDC114 CASP8 ADA IL7R CCDC114 TNFSF12 BTK LRRC56 PEPD BLNK CD55 GRHL3 NBN PRKCD KPTN PMM2 DNAAF3 KDM6A POLA1 RAG1 DNAH11
Protein Mutations 6
A2063G G551D K55R L460D R287Q S1009A
SNP 0